Expanding laparoscopic pancreaticoduodenectomy to pancreatic-head and periampullary malignancy: major findings based on systematic review and meta-analysis

Ke Chen¹, Xiao-long Liu¹, Yu Pan¹, Hendi Maher² and Xian-fa Wang¹*

Abstract

Background: Laparoscopic pancreaticoduodenectomy (LPD) remains to be established as a safe and effective alternative to open pancreaticoduodenectomy (OPD) for pancreatic-head and periampullary malignancy. The purpose of this meta-analysis was to compare LPD with OPD for these malignancies regarding short-term surgical and long-term survival outcomes.

Methods: A literature search was conducted before March 2018 to identify comparative studies in regard to outcomes of both LPD and OPD for the treatment of pancreatic-head and periampullary malignancies. Morbidity, postoperative pancreatic fistula (POPF), mortality, operative time, estimated blood loss, hospitalization, retrieved lymph nodes, and survival outcomes were compared.

Results: Among eleven identified studies, 1196 underwent LPD, and 8247 were operated through OPD. The pooled data showed that LPD was associated with less morbidity (OR = 0.57, 95%CI: 0.41~ 0.78, P < 0.01), less blood loss (WMD = −372.96 ml, 95% CI, −507.83~−238.09 ml, P < 0.01), shorter hospital stays (WMD = −197.49 ml, 95% CI, −304.62~−90.37 ml, P < 0.01), and comparable POPF (OR = 0.85, 95%CI: 0.59~1.24, P = 0.40), and overall survival (HR = 1.03, 95%CI: 0.93~1.14, P = 0.54) compared to OPD. Operative time was longer in LPD (WMD = 87.68 min; 95%CI: 27.05~148.32, P < 0.01), whereas R0 rate tended to be higher in LPD (OR = 1.17; 95%CI: 1.00~1.37, P = 0.05) and there tended to be more retrieved lymph nodes in LPD (WMD = 1.15, 95%CI: -0.16~2.47, P = 0.08), but these differences failed to reach statistical significance.

Conclusions: LPD can be performed as safe and effective as OPD for pancreatic-head and periampullary malignancy with respect to both surgical and oncological outcomes. LPD is associated with less intraoperative blood loss and postoperative morbidity and may serve as a promising alternative to OPD in selected individuals in the future.

Keywords: Laparoscopy, Pancreaticoduodenectomy, Adenocarcinoma, Morbidity, Meta-analysis

* Correspondence: 3195011@zju.edu.cn
1Department of General Surgery, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, 3 East Qingchun Road, Hangzhou 310016, Zhejiang Province, China

© The Author(s). 2018 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background
Pancreatic-head and periampullary malignancy mainly include pancreatic duct adenocarcinoma (PDAC) and periampullary adenocarcinoma (PAAC). PDAC causes a considerable amount of cancer-related death worldwide. In fact, PDAC is the fourth deadliest malignancy in developed countries and is predicted to become the second one within several years [1, 2]. PAAC, defined as malignancy located in the distal common bile duct, ampulla of Vater or adjacent duodenum, are uncommon cancers compared to PDAC. However, despite its relatively higher resectability rates compared with PDAC, the long-term survival outcomes of PAAC patients are poor [3]. These cancers represent great challenges for healthcare providers and require a multidisciplinary approach in which pancreaticoduodenectomy (PD) with lymphadenectomy remains the primary curative treatment for patients without distant metastasis.

Minimally invasive surgery, typically characterized by laparoscopic approach, is one of the main surgical advances in the twenty-first Century [4]. It has been applied to complex pancreatic procedures including laparoscopic PD (LPD) for neoplasms on the pancreatic head and periampullar region or laparoscopic distal pancreatectomy (LDP) for these on the pancreatic body or tail. LDP represents a technique, which is technically less demanding, without any reconstruction, whereas LPD is a demanding procedure, which should be performed only in referral centers by experienced surgeons. Now, several meta-analyses have been published regarding LDP for malignancy treatment [5, 6], there was still no meta-analysis on the potential advantages and disadvantages of LPD for cancers. This meta-analysis proposed to dig deeper into the surgical and oncologic outcomes of patients who suffered from pancreatic-head and periampullary malignancy and underwent LPD versus open PD (OPD).

Methods
Study selection
We systematically searched the relevant literature using PubMed, Embase, Cochrane Library, and EBSCO for articles published up to March 2018 The search terms “minimally invasive”, “laparoscopy”, “Whipple”, “pancreaticoduodenectomy”, “pancreatic ductal adenocarcinoma”, “pancreatic cancer”, “ampullary cancer”, “ampulla of Vater”, and “periampullary neoplasm” were utilized. All eligible studies were retrieved, and their bibliographies were further checked for other potential publications. The language of the publications was confined to English.

Inclusion criteria
Publications included in this study were based on the following criteria: (1) compared LPD and OPD in patients suffering from pancreatic-head and periampullary malignancy (PDAC and PAAC); (2) reported on at least one of the outcome measures mentioned below; and (3) if there was overlap between authors and/or institutions, the higher quality or more recent publication was selected.

Data extraction
Information was independently extracted from eligible studies by two authors (Chen K and Liu XL). The following information was collected: (1) Primary outcomes: morbidity, mortality, postoperative pancreatic fistula (POPF), margin status, retrieved lymph nodes (RLNs), and long-term survival. (2) Secondary outcomes: operative time, intraoperative blood loss, transfusion, and length of hospital stay. The postoperative morbidity was classified according to the Clavien-Dindo classification when possible [7]. POPF were diagnosed in accordance with the International Study Group for Pancreatic Fistula (ISGPF) criteria [8]. Clinically significant POPF was defined as ISGPF grade B/C. Resection margins were considered negative (R0) when no tumor was evident along the transection surface [9].

Quality assessment
The Newcastle-Ottawa Quality Assessment Scale (NOS) was used to evaluate the quality of non-randomized controlled trials (NRCTs). The quality of each study was scored by taking into account patient selection, comparability of the groups and assessment of the outcomes. The scale ranges from 0 to 9 stars: studies with a score ≥ 6 could be deemed as methodologically sound. Randomized controlled trials (RCTs) were assessed by the Jadad scale. High quality RCTs get more than 2 out of a maximum possible score of 5.

Statistical analysis
Statistical analysis was performed using the RevMan 5.1 software (Cochrane Collaboration, Oxford, UK). The odds ratio (OR) or weighted mean differences (WMD) with 95% confidence intervals (CI) were calculated for dichotomous and continuous results, respectively. Medians were converted to means by the method introduced by Hozo et al. [10]. The hazard ratio (HR) was used as a summary statistic for long-term survival. The log HR and its standard error (SE) were analyzed directly if the studies reported the HR and 95% CI. Otherwise, the log HR and its SE were estimated using the method described by Tierney et al. [11]. The fixed-effect model was firstly used for primary and secondary outcomes, and in case of significant heterogeneity (I²>50% or Q test P<0.05) the results were calculated using the random-effect model. Subgroup analysis was carried out according to the tumor primaries (PDAC or PAAC). Funnel plots were used to screen for publication bias based on the R0 rate. The
statistical tests were two-sided, and \( P < 0.05 \) was considered statistically significant.

**Results**

**Study characteristics and quality of included studies**
The search strategy initially generated 668 relevant clinical trials. Of these, articles that did not compare LPD with OPD were excluded based on their titles and abstracts. Thus, 86 articles were selected and a full examination of the text was conducted. A further 73 papers were excluded because the surgical indications of these studies were not restricted to pancreatic-head and periampullary malignancy. Another two publications were then excluded due to overlapping patient cohorts [12, 13]. Finally, a total of 9443 patients [LPD 1196 (12.7%), OPD 8247 (87.3%)] from 11 studies were included [14–24].

**Primary outcomes**

POPF was described in 8 studies [14, 15, 18, 19, 21–24]. Pooling data indicated no significant difference in terms of overall POPF rates between two groups (OR = 0.85, 95%CI: 0.59–1.24, \( P = 0.40 \)) (Fig. 2), as well as the clinically significant POPF rates (OR = 0.86, 95%CI: 0.53–1.41, \( P = 0.56 \)). The morbidity was available from 7 studies [14, 15, 18, 19, 21–23]. The pooled data indicated that the overall postoperative morbidity was significantly decreased in LPD (OR = 0.57, 95%CI: 0.41–0.78, \( P < 0.01 \)) (Fig. 3). Eight studies recorded postoperative mortality [14, 15, 19–24]. Mortality was similar in LPD and OPD for malignancies (OR = 0.88, 95%CI: 0.64–1.20, \( P = 0.41 \)) (Fig. 4). Negative margin (R0) rate was reported in all studies. The difference in R0 rate was not significant in pooling results, but had a tendency to be higher in the LPD group than in the OPD group (OR = 1.17, 95%CI: 1.00–1.37, \( P = 0.05 \)) (Fig. 5). The funnel plot for studies reporting the ORs of R0 was used to detect publication bias. Visual inspection of the funnel plot revealed symmetry, indicating no serious publication bias, as illustrated in Fig. 6.

The RLNs were pooled from 10 studies [14–17, 19–24]. Pooled results revealed a tendency of more RLNs in the LPD group than in the OPD group with a marginal difference (WMD = 1.15, 95%CI: -0.16–2.47, \( P = 0.08 \)) (Fig.7). Six studies reported survival outcomes. The overall survival rate was not found to be different among the two groups (HR = 1.03, 95%CI: 0.93–1.14, \( P = 0.54 \)) (Fig. 8). The primary outcomes of the quantitative meta-analysis were summarized in Table 2.

**Secondary outcomes**

Five studies reported operative time [14, 19, 22–24]. The operative time in LPD group was longer than that in OPD group (WMD = 87.68 min, 95%CI: 27.05–148.32, \( P < 0.01 \)). Also five studies reported blood loss [14, 19, 22–24]. The estimated blood loss was significantly reduced in LPD group (WMD = -197.49 ml, 95% CI, -304.62–-90.37 ml, \( P < 0.01 \)). A similar result was achieved in the field of blood transfusions (OR = 0.64, 95 %CI: 0.50–0.84, \( P < 0.01 \)).
Table 1
Summary of studies included in the meta-analysis

| Author   | Region | Design  | Year | Study Period | Sample size | Indications | Conversion (%) | ITT | ISGPF | Clavien-Dindo | Mortality | Quality scores |
|----------|--------|---------|------|--------------|-------------|-------------|----------------|-----|-------|--------------|-----------|----------------|
| Croome   | USA    | OCS (P,S) | 2014 | 2008–2013 | 108 214 | PDAC | 7(6.5) | Yes | Yes | Yes | 30d | 8 |
| Hakeem   | UK     | OCS (R,S) | 2014 | 2005–2009 | 12 | 12 | PAAC | NR | NR | NR | Yes | 30d | 9 |
| Chen     | China  | OCS (P,S) | 2015 | 2010–2013 | 19 | 38 | PDAC | 1(5.3) | Yes | Yes | Yes | NR | 8 |
| Song     | Korea  | OCS (R,S) | 2015 | 2007–2012 | 11 | 261 | PDAC | NR | No | Yes | Yes | 30d | 8 |
| Dokmak   | France | OCS (P,S) | 2015 | 2011–2014 | 15 | 14 | PDAC | NR | Yes | Yes | Yes | NR | 7 |
| Stauffer | USA    | OCS (P,S) | 2017 | 1995–2014 | 58 | 193 | PDAC | 14(24.1) | Yes | Yes | Yes | 90d | 8 |
| Kantor   | USA    | OCS (R,M) | 2017 | 2010–2013 | 828 | 7385 | PDAC | E | NR | NR | NR | 90d | 8 |
| Conrad   | USA    | OCS (P,S) | 2017 | 2000–2010 | 40 | 25 | Mixed | 9(18.4)a | No | Yes | Yes | 90d | 9 |
| Palanivelu | India | RCT     | 2017 | 2013–2015 | 32 | 32 | Mixed | 1(3.1) | Yes | Yes | Yes | 90d | 3.a |
| Khaled   | UK     | OCS (R,S) | 2017 | 2002–2015 | 15 | 15 | Mixed | 1(6.7) | Yes | Yes | Yes | 30d | 9 |
| Meng     | China  | OCS (R,S) | 2018 | 2010–2015 | 58 | 58 | PAAC | NR | NR | Yes | Yes | 30d | 9 |

OCS observational clinical study, RCT randomized controlled trial, P prospectively collected data, R retrospectively collected data, M muti-centers, S single center, DP distal pancreatectomy, PD pancreatectoduodenectomy, L laparoscopy, O open, ITT intention-to-treat analysis, ISGPF international study group of pancreatic fistula, PJ pancreaticojejunostomy, DTM duct-to-mucosa, E exclude, NR not reported

*a Jadad score

Fig. 2 Forest plot of the meta-analysis: overall POPF
studies reported the length of hospital stay [14, 15, 18–24]. The pooled data indicated a comparable length of hospital stay between groups (WMD = −1.07, 95%CI, −3.05~−0.92, P = 0.29). Tumor size was available except in one study [20]. The tumor size of OPD was larger than that of LPD (WMD = −0.16, 95%CI, −0.31~−0.02, P = 0.03). The secondary outcomes of the quantitative meta-analysis are outlined in Table 2.

**Sensitivity analysis**

One retrospectively multi-institutional study conducted by Kantor et al. [20], in which only PDAC were included, provided the vast majority of cases. The study offered outcomes of mortality, R0 rate, RLNs, overall survival, and length of hospital stay. We investigated the influence of this study on the overall estimated risk by sequentially removing it from the pooled outcomes. We found only the pooling data of R0 rate changed from marginal difference (OR = 1.17, 95%CI: 1.00~1.37, P = 0.05) to no significant difference (OR = 1.28, 95%CI: 0.89~1.84, P = 0.19), whereas the main results presented no obvious changes.

**Discussion**

Minimally invasive PD (MIPD), a laparoscopic surgery, was first described by Gagner and Pompin in 1994, and there has been a recent surge of interest for this demanding technique [25, 26]. PD is a complex procedure and the advantages of minimally invasive approaches used to be closely scrutinized. Although several meta-analyses have confirmed the advantages of MIPD over open surgery, there has been no analysis restricted to malignancy. Moreover, effects of oncologic results were not well evaluated due to insufficient data. In Table 3, we present several previous meta-analyses comparing MIPD to OPD for benign and malignant periampullary disease [27–34].

This meta-analysis selected and summarized the available literature that compared the short-term surgical and long-term survival results of LPD and OPD for malignant periampullary disease. To the best of our knowledge, this is the first meta-analysis comparing LPD versus OPD for the treatment of pancreatic-head and periampullary cancer. No statistically significant differences were identified between the two groups regarding POPF, mortality, overall survival rate, and hospital stay.
Operative time was significantly longer in the LPD group. The differences of R0 rate, and RLNs did not reach statistical significance, but tended to be superior in the LPD group. Moreover, LPD exhibited statistically significant benefits in terms of blood loss, and overall postoperative complications.

The progress of LPD was slow due to the threatening complication of POPF. High rates ranging from 4 to 33% for conventional open surgery were previously reported for both benign and malignant lesions [35, 36]. POPF rates range from 11.8 to 55.2% in LPD for malignancy as reported seemed to somewhat higher than the results above (Table 4). It was also reported that LPD for resection of periampullary tumors was associated with higher morbidity, mainly due to severe POPF [18]. However, our pooling data demonstrated comparable rates, regardless of overall POPFs or clinically significant POPFs between LPD and OPD for malignancy. The approaches which could reduce POPFs also can be completed under laparoscope [37]. The end-to-side, duct-to-mucosa pancreaticojejunostomy (PJ) was now the most commonly performed pancreatic anastomosis approach under laparoscopy just as the conventional open approach [38]. Importantly, our results have shown improved overall morbidity of LPD. Since surgical complications, mainly POPFs, were comparable between the two groups because of the same organ and lymphatic resection area of LPD and OPD, the reduced overall complications may be the result of fewer medical complications. PD involves multiple systems and the complexity of performing three anastomoses can result in enormous surgical trauma, which would result in high risks of medical complications. Pulmonary, cardiovascular, and cerebrovascular morbidities were the most frequent systemic complications in major abdominal surgery. Less bleeding and use of transfusion contribute to preserve stable pulmonary and cardiovascular functions [39]. In addition, less pain and earlier ambulation allows patients to restore physiological homeostasis.

The pooling results show that LPD is linked with a tendency of lower positive margin rate ($P = 0.05$) and more retrieved lymph nodes ($P = 0.08$), two of the oncologic outcomes. Appropriate lymphadenectomy is crucial because elimination of a sufficient quantity of lymph nodes could help to strengthen the staging accuracy and
### Fig. 5 Forest plot of the meta-analysis: R0 rate

| Study or Subgroup | LPD | OPD | Odds Ratio | Odds Ratio |
|-------------------|-----|-----|------------|------------|
|                   | Events | Total | Events | Total | Weight | M-H. Fixed, 95% CI | Year | M-H. Fixed, 95% CI |
| 1.5.1 PDAC        |       |       |         |       |         |          |       |                  |
| Croome            | 84    | 108   | 164     | 214   | 8.3%    | 1.07 [0.61, 1.86] | 2014 |                  |
| Chen              | 18    | 19    | 35      | 38    | 0.4%    | 1.54 [0.15, 15.91] | 2015 |                  |
| Song              | 8     | 11    | 209     | 261   | 1.6%    | 0.66 [0.17, 2.59] | 2015 |                  |
| Dokmak            | 9     | 15    | 7       | 14    | 1.0%    | 1.50 [0.34, 6.53] | 2015 |                  |
| Kantor            | 651   | 828   | 5623    | 7385  | 82.2%   | 1.15 [0.97, 1.37] | 2017 |                  |
| Stauffer          | 49    | 58    | 154     | 193   | 3.7%    | 1.38 [0.62, 3.05] | 2017 |                  |
| Subtotal (95% CI) | 1039  | 8105  | 97.2%   | 1.15 [0.98, 1.35] |          |                  |

**Total events** 819 6192

**Heterogeneity:** Chi² = 1.09, df = 5 (P = 0.96), I² = 0%

**Test for overall effect:** Z = 1.72 (P = 0.09)

### 1.5.2 PAAC

| Study or Subgroup | LPD | OPD | Odds Ratio | Odds Ratio |
|-------------------|-----|-----|------------|------------|
|                   | Events | Total | Events | Total | Weight | M-H. Fixed, 95% CI | Year | M-H. Fixed, 95% CI |
| Hakeem            | 9    | 12   | 8      | 12    | 0.7%    | 1.50 [0.25, 8.84] | 2014 |                  |
| Meng              | 58   | 58   | 55     | 58    | 0.2%    | 7.38 [0.37, 146.12] | 2018 |                  |
| Subtotal (95% CI) | 70   | 70   | 0.8%   | 2.62 [0.82, 11.08] |          |                  |

**Total events** 67 63

**Heterogeneity:** Chi² = 0.84, df = 1 (P = 0.36), I² = 0%

**Test for overall effect:** Z = 1.31 (P = 0.19)

### 1.5.3 Mixed

| Study or Subgroup | LPD | OPD | Odds Ratio | Odds Ratio |
|-------------------|-----|-----|------------|------------|
|                   | Events | Total | Events | Total | Weight | M-H. Fixed, 95% CI | Year | M-H. Fixed, 95% CI |
| Conrad            | 35   | 40   | 21     | 25    | 1.1%    | 1.33 [0.32, 5.53] | 2017 |                  |
| Khaled            | 13   | 15   | 11     | 15    | 0.5%    | 2.36 [0.36, 15.45] | 2017 |                  |
| Palanivelu        | 31   | 32   | 30     | 32    | 0.3%    | 2.07 [0.18, 24.01] | 2017 |                  |
| Subtotal (95% CI) | 87   | 72   | 1.9%   | 1.72 [0.62, 4.77] |          |                  |

**Total events** 79 62

**Heterogeneity:** Chi² = 0.25, df = 2 (P = 0.88), I² = 0%

**Test for overall effect:** Z = 1.05 (P = 0.29)

**Total (95% CI)** 1196 8247 100.0% 1.17 [1.00, 1.37]

**Total events** 965 6317

**Heterogeneity:** Chi² = 3.45, df = 10 (P = 0.97), I² = 0%

**Test for overall effect:** Z = 2.00 (P = 0.05)

**Test for subgroup differences:** Chi² = 1.79, df = 2 (P = 0.41), I² = 0%

---

### Fig. 6 Funnel plots of the R0 rate

![Funnel plots of the R0 rate](image)
**Fig. 7** Forest plot of the meta-analysis: retrieved lymph nodes

| Study or Subgroup | Mean Difference (IV, Random, 95% CI) Year |
|-------------------|-------------------------------------------|
| **LPD**           |                                           |
| 1.6.1 PDAC        |                                           |
| Croome            | 21.4 [0.53, 3.13] 2014                    |
| Song              | -1.20 [-2.22, -0.26] 2015                 |
| Chen              | 0.30 [-3.42, 4.03] 2015                   |
| Stuaffer           | 10.00 [5.40, 14.62] 2017                  |
| Kantor            | 1.00 [0.32, 1.66] 2017                    |
| **Total (95% CI)**| 1.82 [0.42, 4.48]                           |
| **OPD**           |                                           |
| **Subtotal (95% CI)** | 1824 [8091, 18.1%] | 2014 |
| **Heterogeneity: Tau² = 6.62; Chi² = 16.06; df = 4 (P = 0.001); I² = 78%** |
| **Test for overall effect: Z = 1.78 (P = 0.07)** |
| **PAAC**          |                                           |
| Hakeem            | 20.7 [4.83, 9.03] 2014                    |
| Meng              | 1.00 [0.07, 1.93] 2018                    |
| **Subtotal (95% CI)** | 1.82 [0.42, 4.48] | 2014 |
| **Heterogeneity: Tau² = 0.00; Chi² = 0.12; df = 1 (P = 0.73); I² = 0%** |
| **Test for overall effect: Z = 2.18 (P = 0.03)** |
| **Mixed**         |                                           |
| Khaled            | 17.3 [3.20, -1.20] 2017                   |
| Patanaru          | 1.99 [1.30, 1.25] 2017                   |
| Conrad            | 1.00 [0.00001], I² = 96%                 |
| **Total (95% CI)**| 1.82 [0.42, 4.48]                           |
| **Heterogeneity: Tau² = 7.84; Chi² = 47.33; df = 2 (P < 0.00001); I² = 96%** |
| **Test for overall effect: Z = 0.04 (P = 0.97)** |

**Fig. 8** Forest plot of the meta-analysis: overall survival rate

| Study or Subgroup | log(Risk Ratio) | SE | Weight | IV. Fixed, 95% CI Year |
|-------------------|-----------------|----|--------|------------------------|
| **1.7.1 PDAC**    |                 |    |        |                        |
| Croome            | 0.26            | 0.17 | 8.8%  | 1.30 [0.93, 1.81] 2014 |
| Chen              | 0.09            | 0.15 | 11.3% | 1.09 [0.82, 1.47] 2015 |
| Stuaffer           | -0.26           | 0.2  | 6.4%  | 0.77 [0.52, 1.14] 2017 |
| Kantor            | 0.02            | 0.06 | 70.9% | 1.02 [0.91, 1.15] 2017 |
| **Subtotal (95% CI)** | 97.4%            |    |        |                         |
| **Heterogeneity: Chi² = 4.12, df = 3 (P = 0.25); I² = 27%** |
| **Test for overall effect: Z = 0.62 (P = 0.54)** |
| **1.7.2 PAAC**    |                 |    |        |                        |
| Hakeem            | -0.76           | 0.66 | 0.6%  | 0.47 [0.13, 1.71] 2014 |
| **Subtotal (95% CI)** | 0.6%            |    |        |                         |
| **Heterogeneity: Not applicable** |
| **Test for overall effect: Z = 1.15 (P = 0.25)** |
| **1.7.3 Mixed**   |                 |    |        |                        |
| Conrad            | -0.2            | 0.36 | 2.0%  | 0.82 [0.40, 1.66] 2017 |
| **Subtotal (95% CI)** | 2.0%            |    |        |                         |
| **Heterogeneity: Not applicable** |
| **Test for overall effect: Z = 0.56 (P = 0.58)** |
| **Total (95% CI)**| 100.0%          |    | 1.02 [0.93, 1.13] |                        |
| **Heterogeneity: Chi² = 5.94, df = 5 (P = 0.31); I² = 16%** |
| **Test for overall effect: Z = 0.44 (P = 0.66)** |
| **Test for subgroups differences: Chi² = 1.82, df = 2 (P = 0.40); I² = 0%** |
regional tumor control. In addition, curative R0 resection is referred as the most important factor determining, which is deemed the only chance to survival [40], and the prognostic validity of margin status may be primarily confined to pancreatic head cancers rather than neoplasms in body or tail [41]. Elaborate manipulation and better visualization of critical anatomy could explain our outcomes. However, as our results also indicated a shorter tumor size in LPD group, some researches may include LPD cases of small, easily resectable tumors that would be partial to LPD, the benefit of LPD for margin status and lymph nodes harvesting cannot be confirmed, but at least not inferior to open surgery. Long-term survival rate is crucial the outcome for evaluating surgical interventions in oncological therapy. Periampullary cancer, especially PDAC, has significantly more aggressive inherent tumor biology, for which there are hardly any effect of adjuvant therapy [42, 43]. Large series on PDAC reported 5-year survival rates only around 20% [44, 45], and estimated at only 20–50% for PAAC [3, 46]. None of the previous studies on LPD identify survival advantages of the laparoscopic approach, and our analysis

Table 2 Results of the meta-analysis

| Outcomes                      | No. Studies | Sample size LPD | Sample size OPD | Heterogeneity (I²) | Model | Overall effect size | 95% CI of overall effect | P        |
|--------------------------------|-------------|-----------------|-----------------|--------------------|-------|---------------------|--------------------------|---------|
| **Primary Outcomes**          |             |                 |                 |                    |       |                     |                          |         |
| POPF                           | 8           | 338             | 563             | 0.99, 0%           | F     | OR = 0.85           | 0.59~ 1.24               | 0.40    |
| Significant POPF              | 5           | 271             | 512             | 0.96, 0%           | F     | OR = 0.86           | 0.53~ 1.41               | 0.56    |
| Morbidity                     | 7           | 280             | 505             | 0.37, 7%           | F     | OR = 0.57           | 0.41~ 0.78               | < 0.01  |
| Mortality                     | 8           | 1151            | 7934            | 0.98, 0%           | F     | OR = 0.88           | 0.64~ 1.20               | 0.41    |
| R0 rate                       | 11          | 1196            | 8247            | 0.97, 0%           | F     | OR = 1.17           | 1.00~ 1.37               | 0.05    |
| Retrieved lymph nodes         | 10          | 1181            | 8233            | < 0.01, 86%        | R     | WMD = 1.15           | -0.16~ 2.47               | 0.08    |
| Overall survival              | 6           | 1065            | 7867            | 0.31, 16%          | R     | HR = 1.02           | 0.93~ 1.13               | 0.66    |
| **Secondary Outcomes**        |             |                 |                 |                    |       |                     |                          |         |
| Operation time (min)           | 5           | 271             | 512             | < 0.01, 99%        | R     | WMD = 87.68         | 27.05~ 148.32             | < 0.01  |
| Blood loss (mL)                | 5           | 271             | 512             | < 0.01, 96%        | R     | WMD = -197.49       | -304.62~ -90.37           | < 0.01  |
| Transfusion                   | 5           | 296             | 522             | 0.36, 7%           | F     | OR = 0.64           | 0.50~ 0.84               | < 0.01  |
| Hospital stay (days)           | 9           | 1166            | 7948            | < 0.01, 85%        | R     | WMD = -1.07         | -3.05~ 0.92               | 0.29    |
| Tumor size                    | 10          | 368             | 862             | 0.46, 0%           | F     | WMD = -0.16         | -0.31~ -0.02              | 0.03    |

Table 3 Previous meta-analyses comparing MIPD with OPD for benign and malignant periampullary disease

| Variables                      | Corea       | Nigri       | Lei          | Qn           | de Rooij     | Zhang        | Peng         | Shin b    | Shin b   |
|--------------------------------|-------------|-------------|--------------|--------------|--------------|--------------|--------------|-----------|-----------|
| Year                           | 2014        | 2014        | 2014         | 2014         | 2016         | 2016         | 2017         | 2017      | 2017      |
| Included studies               | 6           | 8           | 9            | 11           | 19           | 22           | 9            | 8         | 5         |
| Minimally invasive method      | MIPD        | MIPD        | MIPD         | MIPD         | MIPD         | MIPD         | RPD          | LPD       | RPD       |
| Total MIPD numbers             | 169         | 204         | 209          | 327          | 710          | 1018         | 245          | 450       | 160       |
| POPF                           | NS          | NS          | NS           | NS           | NS           | NS           | NS           | NS        | NS        |
| Morbidity                      | NS          | NS          | NS           | NS a         | N/A          | NS           | Favor RPD    | NS        | NS a      |
| Mortality                      | N/A         | NS          | NS           | NS           | NS           | NS           | N/A          | N/A       | N/A       |
| R0 rate                        | Favor MIPD  | NS          | Favor MIPD   | NS a         | Favor MIPD   | Favor MIPD   | Favor RPD    | NS        | NS        |
| Retrieved lymph nodes          | Favor MIPD  | NS a        | NS           | NS           | NS a         | NS           | NS           | NS        | NS        |
| Survival                       | N/A         | N/A         | N/A          | N/A          | N/A          | N/A          | N/A          | N/A       | N/A       |
| Operation time (min)           | Favor OPD   | Favor OPD   | Favor OPD    | Favor OPD    | Favor OPD    | Favor OPD    | Favor OPD    | Favor OPD  | Favor OPD  |
| Blood loss                     | Favor MIPD  | Favor MIPD  | Favor MIPD   | Favor MIPD   | Favor MIPD   | Favor MIPD   | Favor RPD    | Favor RPD  | Favor RPD  |
| Transfusion                    | N/A         | NS          | Favor MIPD   | N/A          | Favor MIPD   | N/A          | N/A          | N/A       | N/A       |
| Hospital stay (days)           | Favor MIPD  | Favor MIPD  | Favor MIPD   | Favor MIPD   | Favor MIPD   | Favor RPD    | Favor LPD    | Favor RPD  | Favor RPD  |

NS not significant, N/A not available

a not significant but tended to favor MIPD

b one separate study
revealed the HR of overall survival rate was comparable between LPD and OPD. We agree with the viewpoint of Croome et al. that neither the laparoscopic or open procedure was technically superior would largely depend on the technique of surgeon and on pathologic analytic variability. Thus, a technically similar oncologic resection could be performed regardless of whether the open or laparoscopic approach was meticulously used [14].

Regarding the operative time and blood loss, our pooled data indicated similar outcomes to the previous studies (Table 3). Because of the intricate dissection and complicated gastrointestinal, LPD present a more demanding and challenging approach for pancreatic surgeons. Kendrick and Cusati report their initial duration of LPD to be approximately 8 h, which improved to 5 h after approximately 50 cases [47]. Therefore, adequate training and optimizing surgical potency to reduce the operative time is required before LPD becomes a generally accepted and sustainable procedure. Another benefit of laparoscopic surgery lies in the enhanced postoperative recovery. Reduced use of analgesic drugs, shortened time of abdominal cavity exposure, and earlier postoperative activities are considered to be the main reasons.

This systematic review and meta-analysis of LDP versus ODP for pancreatic-head and perianpillary malignancy represents the most comprehensive collection of evidence available within this field. However, the results should still be explained with caution for several limitations. First, only one study was RCT, while others were NRCTs. Selection biases necessarily consist in surgeons’ or patients’ decision on operation and adjuvant therapy. Moreover, various biases are real concerns because hardly any of the included studies employed standardized appraisal for the end points. Second, clinical heterogeneity needs significant attention. The surgical techniques, take the different the histopathological protocols were variable in both open and laparoscopic groups. Third, there are biological differences between PDAC and PAAC. Although a subgroup analysis was conducted, we should still admit various

| Table 4 Studies on LPD for pancreatic cancer |
|---------------------------------------------|
| CROOME | Hakeem | Chen | Song | Dokmak | Staufier | Kantor | Condor | Palanivelu | Khaled | Meng |
| Age (years) | 66.6 ± 9.6 | 67.0 ± 10.2 | – | 68.1 ± 7 | – | 69.9 (40.6–84.8) | 65.9 ± 10.7 | 68 (45–83) | 57.8 ± 2.0 | 65 | (35–78) | 60 ± 9.1 |
| Sex (M/F) | 57/51 | 8/4 | – | – | – | 32/26 | – | 26/14 | 18/14 | 8/7 | 32/26 |
| BMI | 27.4 ± 5.4 | 25.8 ± 3.7 | – | – | – | 25.9 (17.7–49.6) | – | 23.9 | (14.9–34.1) | 24.9 ± 0.7 | 23.4 | (18–26) |
| Tumor size (cm) | 3.3 ± 1.0 | 2.0 ± 1.0 | – | – | – | 2.8 ± 0.6 | 2.4 (1.5–4) | 2.5 (0.3–10.0) | – | 2.5 | (0.3–8.0) |
| Retrieved LNs | 21.4 ± 8.1 | 20.7 ± 6.3 | 1.4 ± 0.8 | 20.7 ± 6.3 | 18.1 ± 6.6 | 20.8 (59–95) | 15 ± 10 | 20(8–118) | 14.9 ± 6.6 | 20 | (1.5–26) |
| Operative time (min) | 379.4 ± 519.3 | – | – | – | – | 518 (313–761) | – | 359 ± 14 | 470 | (280–660) | 475 |
| Blood loss (mL) | 492.4 ± 519.3 | – | – | – | – | 250 (50–8500) | – | 250 ± 22 | 300 | (50–600) | 200 |
| POPF | – | 16.7% | – | – | 20% | 11.8% | – | 30% | 15.6% | 20.0% | 55.2% |
| Significant | 11% | – | – | – | – | 7.8% | – | – | 6.3% | 20.0% | 13.8% |
| Morbidity | 5.6% CD>2 | 58.3% | – | – | 53% | 53.4% | – | 95% | 25.0% | 40.0% | 15.5% |
| Hospital stay (days) | 6 (4–118) | 14.9 ± 6.6 | – | – | 15 (6–53) | 6 (4–68) | 10.2 ± 8.5 | 24.5 | (9–311) | 7 (5–52) | 9 (7–20) |
| Readmission | – | – | – | – | – | 22.4% 90d | 6.8% 30d | – | 6.3% 90d | – |
| Mortality | 0.9% 30d | 0% 30d | – | 0% 30d | 0% 90d | 3.4% 90d | 6.9% 90d | 5% 90d | 3.1% 90d | 0% 30d | 1.7% 30d |
| Survival | MS: 253 m | 1.3,5y-DFS:100, 92.83%; 13,5y-Os:100, 92.75% | – | 1.3,5y-DFS:25.7%; 13,5y-Os:80.5, 49.2, 39.7% | Sy-Os:53.6% | – | 1.2,3,4,5y-Os:66.5,43.3,43.3,38,32,31% | MS: 20.7 m | MS: 35.5 m; 1.3,5y-DFS:62.3, 37.9, 25.7%; 1,3,5y-Os:80.5, 49.2, 39.7% | – | 1,3,5y-Os:100, 80, 67% |

OS overall survival rate, MS median survival time, m month
histologies powered our outcomes because several studies did not differentiate PDAC and PAAC in their studies, and even in PAAC, there are several different histologies. Last but not least, it should be kept in mind that these studies were on behalf of the best centers’ experience on LPD around the world. The literature showed that specialization in pancreatic surgery results in both better short- and long-term survival [48]. Obtained conclusions might not be feasible in less specialized centers.

Conclusions
Our meta-analysis demonstrated that in contrasted to OPD, LPD could achieve short-term advantages within blood loss, and postoperative morbidity for pancreatic-head and periampullary malignancy. Moreover, both procedures have comparable oncological and long-term survival outcomes. LPD may serve as a promising alternative to OPD in selected individuals suffered pancreatic-head and periampullary malignancy. However, taking into account all the limitations of the study, methodologically high-quality controlled clinical trials are necessary for further evaluation. Anyway, we believe our study could serve as a useful background for future researches.

Abbreviations
CI: Confidence intervals; HR: Hazard ratio; ISGPF: International Study Group for Pancreatic Fistula; LDP: Laparoscopic distal pancreatectomy; LPD: Laparoscopic pancreaticoduodenectomy; MIPD: Minimally invasive pancreaticoduodenectomy; NOS: Newcastle-Ottawa Quality Assessment Scale; NRCT: Nonrandomized comparative study; OPD: Open pancreaticoduodenectomy; OR: Odds ratio; PAAC: Periampullary adenocarcinoma; PD: Pancreaticoduodenectomy; PDAC: Pancreatic duct adenocarcinoma; RCT: Randomized controlled trial; RLN: Retrieved lymph nodes; RPD: Robotic pancreaticoduodenectomy; SD: Standard deviation; SE: Standard error; WMD: Weighted mean difference

Availability of data and materials
The datasets analyzed during the current study available from the corresponding author on reasonable request.

Authors’ contributions
KC and YP designed the study; XLL collected relevant literature and conducted the analysis of pooled data; KC and HM wrote the manuscript; XFproofread and revised the manuscript. All authors have approved the version to be published.

Ethics approval and consent to participate
Not applicable.

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author details
1Department of General Surgery, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, 3 East Qingchun Road, Hangzhou 310016, Zhejiang Province, China. 2School of Medicine, Zhejiang University, 866 Yuhangtang Road, Hangzhou 310058, Zhejiang Province, China.

Received: 3 April 2018 Accepted: 21 June 2018

Published online: 03 July 2018

References
1. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65(2):87–108.
2. Rahib L, Smith BD, Aizenberg R, Rosenzweig AB, Fleschner JM, Mattisson LM. Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res. 2014;74(11):2913–21.
3. Neoptolemos JP, Moore MJ, Cox TF, Vallee JW, Palmer DH, McDonald AC, Carter R, Tebbutt NC, Dervenis C, D’Ambra M, Pagano N, Di Marco MC, Minni F. Laparoscopic versus open distal pancreatectomy for ductal adenocarcinoma: an ESPAC-3 periampullary cancer randomized trial. Jama. 2012;308(2):147–56.
4. Gawande A. Two hundred years of surgery. N Engl J Med. 2012;366(18):1716–23.
5. Ricci C, Casadei R, Taffurelli G, Toscano F, Paolillo CA, Bogoni S, D’Ambra M, Pagano N, Di Marco MC, Minni F. Laparoscopic versus open distal pancreatectomy for ductal adenocarcinoma: a systematic review and meta-analysis. J Gastrointest Surg. 2015;19(4):770–81.
6. Riviere D, Gurusamy KS, Kooby DA, Vollmer CM, Besselink MG, Davidson BR, van Laarhoven CJ. Laparoscopic versus open distal pancreatectomy for pancreatic cancer. Cochrane Database syst Rev. 2016;4:CD011391.
7. Clavien PA, Barkun J, de Oliveira ML, Vauthey JN, Dindo D, Schuilk RD, de Santibanes E, Pekolj J, Slankamenac K, Bassi C, et al. The Clavien-Dindo classification of surgical complications: five-year experience. Ann Surg. 2009;250(2):187–96.
8. Bassi C, Dervenis C, Butturini G, Fingerhut A, Yeo C, Izibicki J, Neoptolemos J, Sarr M, Traufler W, Buchler M. Postoperative pancreatic fistula: an international study group (ISGPF) definition. Surgery. 2005;138(1):18–33.
9. Wietkink C, Compton C, Quirke P, Nagtegaal I, Merkel S, Hermanek P, Sobin LH. A uniform residual tumor (R) classification: integration of the R classification and the circumferential margin status. Cancer. 2009;115(15):3483–8.
10. Hozo SP, Djulbegovic B, Hozo I. Estimating the mean and variance from the median, range, and the size of a sample. BMC Med Res Methodol. 2005;5:13.
11. Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials. 2007;8:16.
12. Sharpe SM, Talamonti MS, Wang CE, Prinz RA, Roggin K, Bentrem DJ, Winchester DJ, Marsh RD, Stocker SJ, Baker MS. Early National Experience with laparoscopic Pancreaticoduodenectomy for ductal adenocarcinoma: a comparison of laparoscopic Pancreaticoduodenectomy and open Pancreaticoduodenectomy from the National Cancer Data Base. J Am Coll Surg. 2015;221(1):175–84.
13. Nussbaum DP, Adam MA, Youngwirth LM, Ganapathi AM, Roman SA, Tyler DS, Sosa JA, Blazer DG 3rd. Minimally invasive Pancreaticoduodenectomy does not improve use or time to initiation of adjuvant chemotherapy for patients with pancreatic adenocarcinoma. Ann Surg Oncol. 2016;23(3):1026–33.
14. Croome KP, Farnell MB, Que FG, Reid-Lombardo KM, Truty MJ, Nagorney DM, Kendrick ML. Total laparoscopic pancreaticoduodenectomy for pancreatic ductal adenocarcinoma: oncologic advantages over open approaches. Ann Surg. 2014;260(4):633–8.
15. Hakeem AR, Verbeke CS, Caims A, Aldouri A, Smith AM, Menon KV. A matched-pair analysis of laparoscopic versus open pancreaticoduodenectomy: oncological outcomes using Leeds pathology protocol. Hepatobiliary Pancreat Dis Int. 2014;13(4):435–41.
16. Chen S, Chen JZ, Zhan Q, Deng XX, Shen BY, Peng CH, Li HW. Robotic-assisted laparoscopic versus open pancreaticoduodenectomy: a prospective, matched, mid-term follow-up study. Surg Endosc. 2015;29(12):3698–711.
17. Song KB, Kim SC, Hwang DW, Lee JH, Lee DJ, Lee JW, Park KM, Lee YJ. Matched case-control analysis comparing laparoscopic and open pylorus-preserving Pancreaticoduodenectomy in patients with periampullary tumors. Ann Surg. 2015;262(1):146–55.
18. Dokmak S, Fricheche FS, Aussillous B, Bensaffa Y, Levy P, Ruszniewski P, Belghiti J, Sauvanet A. Laparoscopic pancreaticoduodenectomy should not be routine for resection of periampullary tumors. J Am Coll Surg. 2015;220(5):831–8.
38. Sun YL, Zhao YL, Li WQ, Zhu RT, Wang WJ, Li J, Huang S, Ma XX. Total laparoscopic versus open pancreaticoduodenectomy for pancreatic adenocarcinoma: long-term results at a single institution. Surg Endosc. 2017;31(5):2233–41.

39. Ramana CV, DeBerge MP, Kumar A, Alia CS, Durbin JE, Enelow RL. Inflammatory impact of IFN-gamma in CD8+ T cell-mediated lung injury is mediated by both Stat-1-dependent and -independent pathways. Am J Physiol Lung Cell Mol Physiol. 2015;308(7):L650–7.

40. Howard TJ, Krug JE, Yu J, Zyromski NI, Schmidt CM, Jacobson LE, Madura JA, Wiebke EA, Lillermoe KD. A margin-negative R0 resection accomplished with minimal postoperative complications is the surgeon’s contribution to long-term survival in pancreatic cancer. J Gastrointest Surg. 2006;10(10):1338–45. discussion 1345-1336

41. Demir IE, Jager C, Schlitter AM, Konukiewitz B, Stecher L, Schorn S, Tieftrunk E, Scheufler F, Calavrezo L, Schrenn R, et al. RO versus R1 resection matters after Pancreatecoduodenectomy and less after distal or Total Pancreatectomy for pancreatic Cancer. Ann Surg. 2017;267:508–16.

42. Youngwirth LM, Nussbaum DP, Thomas S, Adam MA, Blazer DG 3rd, Roman SA, Sosa JA. Nationwide trends and outcomes associated with neoadjuvant therapy in pancreatic cancer: an analysis of 18,243 patients. J Surg Oncol. 2017;116(2):127–32.

43. Acharia A, Markar SR, Sodergren MH, Malietzis G, Darzi A, Athanasiou T, Khan AZ. Meta-analysis of adjuvant therapy following curative surgery for periampullary adenocarcinoma. Br J Surg. 2017;104(7):814–22.

44. Luo J, Xiao L, Wu C, Zheng Y, Zhao N. The incidence and survival rate of population-based pancreatic cancer patients: shanghai Cancer registry 2004-2009. PLoS One. 2013;8(10):e76052.

45. Dixler M, Ruckert F, Hunger M, Kersting S, Pilarsky C, Saeger HD, Grutzmann R. Evaluation of survival in patients after pancreatic head resection for ductal adenocarcinoma. BMC Surg. 2013;13:12.

46. Kim K, Chee EK, Jiang JY, Kim SW, Oh DY, Im SA, Kim TY, Bang YJ, Ha SW. Role of adjuvant chemoradiotherapy for amputaion of Vater cancer. Int J Radiat Oncol Biol Phys. 2009;75(2):436–41.

47. Kendrick MC, Cusati D. Total laparoscopic pancreaticoduodenectomy: feasibility and outcome in an early experience. Arch Surg. 2010;145(1):19–23.

48. Ahola R, Siki A, Vaisma K, Vornanen M, Sand J, Laula Kari J. Effect of centralization on long-term survival after resection of pancreatic ductal adenocarcinoma. Br J Surg. 2017;104(11):1532–8.